Skip to main content Accessibility help
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 8 - Application of pharmacogenomics and personalized medicine for the care of depression

  • Edited by Chad E. Beyer, Stephen M. Stahl, University of California, San Diego
  • Book:
    Next Generation Antidepressants
    Published online:
    19 October 2021
    Print publication:
    20 May 2010, pp 119-131

  • Summary

    Remarkable progress notwithstanding, pharmacotherapy for depressive and related conditions, as well as pharmacological intervention of various other psychiatric and medical conditions, has typically ignored the magnitude and clinical relevance of the huge inter-individual variations in pharmacokinetics and pharmacodynamics. Such neglects lead to additional risks of severe and/or unpleasant side effects, medication non-adherence, prolonged periods of titration, suboptimal therapeutic responses, and treatment failures. Advances in pharmacogenomics and computer modeling technologies hold promises for achieving the goals of “personalized” (“individualized”) medicine. However, challenges abound for realizing such goals, including the packaging and interpretation of genotyping results, ethical considerations, financing, economy of scale, inertia against changes in medical practice (innovation diffusion), as well as other infrastructural and organizational issues related to the use of new information.